Primary RPLND Versus Systemic Chemotherapy in Good-prognosis Metastatic Testicular Cancer

The goal of this prospective observational study is to learn about the short- and long-term effects of treating men over the age of 18 with good prognosis metastatic testicular cancer with either primary retropertioneal lymph node dissection, RPLND, (for low-stage metastastic seminoma) or three doses of chemotherapy for metastastic seminoma or nonseminoma. The main question it aims to answer is: Does primary RPLND lower the risk of side-effects compared to receiving chemotherapy?

NCT Number	NCT07498959
Lead Sponsor	Sahlgrenska University Hospital Collaborators: Karolinska University Hospital, Haukeland University Hospital, University Hospital of North Norway, Oslo University Hospital, Trondheim University Hospital, Uppsala University Hospital, University Hospital, Umeå, Lund University Hospital
Conditions	Testicular Cancer, Seminoma, Quality of Life, De-escalation, RPLND
Enrollment	160 participants
Start Date	2026-03-19
Primary Completion	2031-03-25 (estimated)
Study Completion	2032-03-25 (estimated)
Updated on ClinicalTrials.gov	2026-03-27